News | News By Subject | News by Disease News By Date | Search News

Glaucoma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Amid Insider Trader Investigations, Acucela (AUCL) and Otsuka Pharma Kill Glaucoma Drug Deal After Failed Trial     6/14/2016
Gilead (GILD) May Take Page Out of Pfizer (PFE)'s Game Plan as Firm Hunts for M&As to Sustain Growth     2/4/2016
Aerie (AERI) Shares Soar After Glaucoma Drug Meets Late Stage Endpoints     9/17/2015
Aerie (AERI) Freefalls Aftermarket as Rhopressa Fails Phase III Study     4/27/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
NicOx SA (COX.PA) Gets Boost From Strong Prospects For Glaucoma Drug Vesneo     9/25/2014
Aerie Pharmaceuticals, Inc. (AERI) Soars As Combo Eye Drug Roclatan Performs Well In Phase 2b Trial; Stock Up +28.29% At Market Close (June 25, 2014)     6/26/2014
Amakem NV to Present Top-Line Clinical Results for its Lead Candidate, AMA0076, at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Meeting 2013     11/7/2013
Inotek Pharmaceuticals Corporation Collects $21 Million for Development of Glaucoma Drug     9/27/2013
FDA Approves Novartis AG (NVS)'s Simbrinza for Glaucoma     4/22/2013
Sucampo Pharmaceuticals, Inc. (SCMP) Gets Nod for Glaucoma Drug From FDA     12/12/2012
Aerie Pharmaceuticals, Inc. Gets Good News on Glaucoma Treatment     11/2/2012
FDA Approves Merck & Co., Inc. (MRK) Drug for Glaucoma     2/15/2012

News from Around the Web
5 Daring Biopharmas Mixing Drugs With Marijuana     2/6/2017
Smoking Pot May Give You Better Night Vision     11/1/2016
Why Apnea Patients Are Prone To Suffer From Glaucoma, Hokkaido University Study     7/25/2016
New Eye Test Could Detect Glaucoma Years Earlier, University of New South Wales Study     7/13/2016
Current Stimulation Of The Brain Restores Vision In Patients With Glaucoma And Optic Nerve Damage, Otto-von-Guericke University Of Magdeburg Study     6/30/2016
Green, Leafy Vegetable May Lower Glaucoma Risk, Brigham and Women's Hospital Study     1/15/2016
Three New Glaucoma-Related Genes Discovered, National Eye Institute Researchers Reveal     1/12/2016
Tiny Medical Device Helps Treat Glaucoma     8/13/2015
Newcomers Like Aerie Pharmaceuticals, Inc. (AERI), Inotek Pharmaceuticals Corporation Aim to Shake Up Big Pharma With New Wave of Glaucoma Drugs     2/10/2015
Most Commonly Prescribed Glaucoma Drug Reduces Risk Of Vision Loss By More Than 50% Over 2 Years: Lancet     12/19/2014
Migraine Pain Stopped With Glaucoma Medicine, Doctors Say     9/12/2014
Glaucoma May Be A Brain Disease, Association for Research in Vision & Ophthalmology Reveals     6/10/2014
New Eye Layer Has Possible Link To Glaucoma, University of Nottingham Study     2/18/2014
Glaucoma Drug Can Cause Droopy Eyelids, Massachusetts Eye and Ear Study     5/22/2013
Rapid Eye Movements Significantly Delayed in People With Glaucoma, St. Michael's Hospital Study     12/7/2012

Press Releases
Alcon (ACL) Announces EU Launch Of Cypass Micro-Stent, A Micro Invasive Glaucoma Surgical Device, To Lower Intraocular Pressure (IOP) In Patients With Primary Open-Angle Glaucoma     4/26/2017
Sight Sciences Announces Health Canada Approval Of The VISCO 360 Viscosurgical System For Standalone Microinvasive Glaucoma Surgery (MIGS)     4/13/2017
Bausch & Lomb And NicOx SA (COX.PA) Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod     3/21/2017
Glaukos Announces Five-Year Extensions For Three Category III CPT Codes Related To Micro-Invasive Glaucoma Surgery     3/16/2017
Bausch & Lomb And NicOx SA (COX.PA) Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod     2/27/2017
Santen And twoXAR Announce Strategic Research Collaboration To Discover New Glaucoma Treatments     2/23/2017
NicOx SA (COX.PA) Announces The Presentation Of NCX 667 Scientific Data At AOPT 2017     2/21/2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma     2/3/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering     1/24/2017
Ivantis Nabs $25 Million Series C for Hydrus Microstent     1/10/2017
Inotek (ITEK) Plunges On Failed Phase III Glaucoma Trial     1/3/2017
USC Roski Eye Institute Conducted Patient Trials For Breakthrough Refractory Glaucoma Treatment     11/23/2016
Allergan (AGN) Wins FDA Nod for the XEN Gel Stent, a New Surgical Treatment for Refractory Glaucoma     11/22/2016
Envisia Therapeutics Releases ENV515 (Travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single Dose In Patients With Glaucoma     10/17/2016
Ocular Therapeutix (OCUL) Begins Enrollment In First Phase 3 Clinical Trial With OTX-TP (Sustained Release Travoprost) For The Treatment Of Glaucoma And Ocular Hypertension     10/5/2016